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Abstract
Background:  NBS1 is a key DNA repair protein in the homologous recombination repair
pathway and a signal modifier in the intra-S phase checkpoint that plays important roles in
maintaining genomic stability. The NBS1 8360G>C (Glu185Gln) is one of the most commonly
studied polymorphisms of the gene for their association with risk of cancers, but the results are
conflicting.
Methods: We performed a meta-analysis using 16 eligible case-control studies (including 17 data
sets) with a total of 9,734 patients and 10,325 controls to summarize the data on the association
between the NBS1 8360G>C (E185Q) polymorphism and cancer risk.
Results: Compared with the common 8360GG genotype, the carriers of variant genotypes (i.e.,
8360 GC/CC) had a 1.06-fold elevated risk of cancer (95% CI = 1.00–1.12, P = 0.05) in a dominant
genetic model as estimated in a fixed effect model. However, the association was not found in an
additive genetic model (CC vs GG) (odds ratio, OR = 0.98, 95% CI = 0.85–1.13, P = 0.78) nor in a
recessive genetic model (CC vs GC +GG) (OR = 0.94, 95% CI = 0.82–1.07, P = 0.36). The effect
of the 8360G>C (E185Q) polymorphism was further evaluated in stratification analysis. It was
demonstrated that the increased risk of cancer associated with 8360G>C variant genotypes was
more pronounced in the Caucasians (OR = 1.07, 95% CI = 1.01–1.14, P = 0.03).
Conclusion: Our meta-analysis suggests that the NBS1 E185Q variant genotypes (8360 GC/CC)
might be associated with an increased risk of cancer, especially in Caucasians.
Background
DNA damage may increase cancer risk, and DNA double-
strand breaks (DSBs) cause the most potentially serious
damage to the genome. If unrepaired, DSBs may lead to
genomic instability and thus cancer [1]. The repair of
DSBs in human cells includes two different pathways,
homologous recombination repair (HR) and non-homol-
ogous end joining (NHEJ) pathways [2]. The initial step in
Published: 24 April 2009
BMC Cancer 2009, 9:124 doi:10.1186/1471-2407-9-124
Received: 26 March 2008
Accepted: 24 April 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/124
© 2009 Lu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:124 http://www.biomedcentral.com/1471-2407/9/124
Page 2 of 10
(page number not for citation purposes)
both pathways is the recognition and signaling of DNA
DSBs by a protein complex containing Nijmegen breakage
syndrome 1 (NBS1), meiotic recombination 11 homo-
logue (MRE11), and human RAD50 homologue (RAD50)
proteins [3]. NBS1 plays an important role as a sensor in
repairing the DSBs and activates the cell-cycle checkpoint
signaling; it also directly binds to the phosphorylated his-
tone H2AX that is located around DSBs, participating in
maintaining genomic stability [4], and prevents cells from
telomeric fusion [2,5]. A markedly impaired DSB repair
was observed in cells from patients with Nijmegen break-
age syndrome [6], in which cells are characteristic of chro-
mosome instability and sensitivity to DSB-causative
agents [7,8].
The NBS1 gene is located on human chromosome 8q21
and codes for a protein termed nibrin (754-amino acid
protein) [9-11]. Some NBS1  mutations and polymor-
phisms have been reported to be associated with risk of
several cancers, including cancers of the breast, lung, blad-
der, ovaries, non-Hodgkin lymphoma, malignant
melanoma and basal cell carcinoma of the skin [12-18]. A
homozygous 5-bp deletion in exon 6 (657del5) has been
reported to be associated with an elevated risk of breast
cancer in Polish and Russian populations [15,19]. How-
ever, the 657del5 variant appears to be a Slavic origin with
a low frequency of approximate 0.5% in Eastern Europe
populations and even lower in other ethnic groups.
According to the Environmental Genome Project (EGP)
SNP database of the (NIEHS) (http://egp.gs.washing
ton.edu, accessed on March 1, 2008), 249 single nucle-
otide polymorphisms (SNPs) are reported, of which 84
are common polymorphisms (with a minor allele fre-
quency > 5%). Among these SNPs, the 8360G>C
(Glu185Gln, E185Q, rs1805794) is one of the most com-
monly studied polymorphisms. However, the results of
studies on association between the 8360G>C (E185Q)
polymorphism and the risk of cancers are conflicting
[1,20,21]. To summarize the published data, we per-
formed a meta-analysis from all eligible case-control stud-
ies to assess the association between the NBS1 E185Q
polymorphism and cancer risk.
Methods
Bioinformatics Analysis
Based on the resequencing information about the NBS1
gene provided by the NIEHS Environmental Genome
Project http://egp.gs.washington.edu/data/nbs1/, we cal-
culated the D' value and r2 coefficient by linkage disequi-
librium (LD) analysis. In addition, we further analyzed
SNPs in LD with 8360G>C in a 5-Mb region on chromo-
some 8 via the HapMap SNP database (release #36, http:/
/www.hapmap.org/, March 1, 2008) that have genotypes
for the CEPH trios with the ssSNPer web interface http://
gump.qimr.edu.au/general/daleN/ssSNPer/[22].
Literature search strategy for identification of the studies
We carried out a literature search in the PubMed and Sci-
Finder Scholar (CA web version) database (between Janu-
ary 2000 and February 2008) to identify all articles that
investigated the association between the NBS1  E185Q
polymorphism and cancer risk in all ethnic groups, using
the following keywords and subject terms: 'NBS1,' 'can-
cer,' and 'polymorphism.' We evaluated the titles and
abstracts of all relevant publications first but excluded
abstracts, case reports, editorials, and review articles. Stud-
ies included in the current meta-analysis had to meet the
following criteria: (a) The study used a case-control study
design; (b) the report described cancer diagnoses and the
sources of cases and controls; (c) the report had available
genotype frequency; (d) the authors offered the size of the
samples, odds ratios (ORs) and their 95% confidence
intervals (CIs); (e) the definition of the exposure or risk
genotypes was similar in all reports; and (f) the methods
of data collection and analysis were statistically accepta-
ble.
Data extraction
Data were collected on the NBS1  E185Q genotype for
studies of different types of cancers. The first author, a year
of publication, country, ethnicity of the study population,
and the number of cases and controls and allele frequency
were also described.
Methods for quantitative synthesis
The Hardy-Weinberg equilibrium (p2 + 2pq + q2 = 1, where
p is the frequency of the variant allele and q = 1 - p), was
tested by goodness-of-fit Chi-square tests to compare the
observed genotype frequencies with expected genotype
frequencies in cancer-free controls for all studies. The
selections of published studies used for meta-analysis
were further evaluated in sensitivity analyses. Odds ratio
(OR) and 95% confident interval (CI) in each case-con-
trol study was used to assess the strength of association
between the NBS1 8360G>C (E185Q) genotypes and the
risk of cancer in dominant (GC+CC vs GG), additive (CC
vs GG), and recessive (CC vs GC +GG) genetic models. The
combined OR was calculated according to the method of
Woolf [23]. A χ2-based Q statistic test was performed to
assess the between-study heterogeneity [24]. If the P value
of heterogeneity test was ≥ 0.10, a fixed effect model using
the Mantel-Haenszel method was used to calculate the
combined OR, which assumed the same homogeneity of
the effect size across all the studies. If the P value of the
heterogeneity test was <0.10, it showed that the heteroge-
neity between-study was statistically significant. The ran-
dom effects model using the DerSimonian and Laird
method was performed to calculate the combined OR
[25]. If there was no between-study heterogeneity, the
results from those two methods calculating the combined
OR would be identical. The significance of the combinedBMC Cancer 2009, 9:124 http://www.biomedcentral.com/1471-2407/9/124
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OR was determined by the Z-test, in which P< 0.05 was
considered significant. Finally, combined ORs and their
95% CIs were presented. Stratification analyses for differ-
ent types of cancers were conducted for breast cancer, lung
cancer, bladder cancer, basal cell carcinoma, and other
cancers (i.e., ovarian, prostate, or colorectal cancer) to
estimate cancer-specific OR. Stratification analyses by eth-
nicity were also conducted for Caucasian, Asian and Afri-
can Americans populations to estimate ethnic-specific
ORs.
Publication bias was assessed with the funnel plot, in
which the standard error of log (OR) of each study was
plotted against its OR value. An asymmetric plot sug-
gested possible publication bias by the method of the
Egger's linear regression test [26]. The significance of the
intercept was determined by the Student t-test as sug-
gested by Egger. If the P-value of Egger's linear regression
test was less than 0.05, it meant that there was publication
bias in the meta-analysis.
The SAS/Genetics software program (Version 9.1, SAS
Institute, Inc., Cary, NC, USA) was used to determine the
LD of SNP pairs and Hardy-Weinberg equilibrium. Other
statistical software used included SPSS12.0 for windows
software (SPSS Inc., Chicago, USA), software Stata version
7.0, and Review Manager (version 4.2, the Cochrane Col-
laboration). All P-values were two-sided.
Results
Literature search and meta-analysis databases
We found 31 epidemiologic studies using the search by
'NBS1,' 'cancer' and 'polymorphism' through Pubmed
and SciFinder Scholar (CA web version). Of these 31 stud-
ies, 15 studies were excluded, 9 studies were excluded
because they were not case-control studies [27-35], 5 stud-
ies were excluded because E185Q polymorphism or its
genotype frequency was not reported [14,36-39], and one
studies focused on hematotoxicity but not cancer [40].
The remaining 16 case-control studies included 17 data
sets (because Millian's study included two populations:
African-American and whites) [1,13,16-18,20,21,41-49].
All the articles used DNA from blood samples for geno-
typing. We established a database for the extracted infor-
mation from each article. Table 1 shows the essential
information, including first author, cancer type, year of
the publication, the numbers of cases and controls, and
frequencies of NSB1 8360 C allele for all studies. There
were six studies for breast cancer [1,20,21,41,42], three for
the lung cancer [18,43,44], three for the bladder cancer
Table 1: Summary of eligible studies considered in the meta-analysis
First author(year) Country Ethnicity Cancer type Type of study Case no. Control no. C Allele frequency 
(%) case/control
Kuschel(2002)[1] Germany Caucasians Breast cancer Population-based 1694 734 34.3/32.2
Forsti(2004)[20] Finland Caucasians Breast cancer Population-based 223 319 35.7/38.6
Millikan 
(2005)[41]
North Carolina African-American Breast cancer Hospital-based 726 681 25.1/23.6
Millikan 
(2005)[41]
North Carolina Caucasians Breast cancer Hospital-based 1273 1136 31.6/32.3
Lu(2006)[21] USA Caucasians Breast cancer Hospital-based 421 423 35.9/29.7
Zhang (2005)[42] China Chinese Breast cancer Hospital-based 220 310 35.9/38.2
Lan(2005)[18] China Chinese Lung cancer Population-based 118 111 57.2/66.7
Ryk (2006)[43] Sweden Caucasians Lung cancer Hospital-based 177 152 -/-
Zienoldding 
(2006)[44]
Norway and of 
Norwagian
Caucasians Lung cancer Hospital-based 376 310 34.4/28.5
Broberg 
(2005)[16]
Sweden Caucasians Bladder cancer Hospital-based 61 154 36.1/37.3
Sanyal (2004)[45] Sweden Caucasians Bladder cancer Hospital-based 299 278 38.5/34.2
Figueroa(2007)[48
]
Spanish Caucasians Bladder cancer Hospital-based 1086 1020 31.8/30.0
Festa (2005)[17] Sweden and 
Finland
Caucasians Basal cell 
carcinoma
Hospital-based 241 574 37.1/36.8
Thirumaran 
(2006)[46]
Hungary, Romania, 
and Slovakia
Caucasians Basal cell 
carcinoma
Hospital-based 529 533 35.6/32.4
Auranen 
(2005)[13]
Combined* Caucasians Ovarian cancer Mixed§ 1586 2685 32.7/33.3
Hebbring 
(2006)[47]
Finland Caucasians Prostate cancer Population-based 200 200 35.5/35.8
Pardini (2008)[49] Czech Republic Caucasians Colorectal cancer Hospital-based 532 532 31.8/34.0
*: United Kingdom SEARCH study. Danish MALOVA study. United States FROC study. United Kingdom Royal Marsden Hospital and young ovarian 
cancer study (UK RMH/YOV).
§: Subjects including population and hospital source.BMC Cancer 2009, 9:124 http://www.biomedcentral.com/1471-2407/9/124
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[16,45,48], two for the basal cell carcinoma [17,46], one
for the ovarian [13], one for prostate cancer [47], and one
for colorectal cancer [49]. Among 17 eligible datasets
included in the final analysis, there were 14 (82.3%) of
Caucasians, two (11.8%) of Chinese, and one (5.9%) of
African-Americans. Additional information is listed in the
forest plots in our meta-analyses.
The frequency distributions of genotypes in control
groups from all studies were in accordance with Hardy-
Weinberg equilibrium (P > 0.05), except for Hebbring's
study (χ2 = 3.93, P = 0.05). We performed a sensitivity
analysis to for the selection of published studies in the
meta-analysis. The frequencies of the 8360 C allele in the
control groups are also listed in Table 1. Compared with
the reported frequency from the database of HapMap
http://www.hapmap.org/cgi-perl/gbrowse/
hapmap20_B35/, the frequencies of 8360 C allele in the
meta-analysis were not as similar as that from the Interna-
tional HapMap Project. There might be population diver-
sity. We would take that into account in the meta-analysis.
Test for heterogeneity
Table 2 shows that no between-study heterogeneity was
found in C vs G allele comparison for 16 datasets (P =
0.10) and in dominant genetic models for all 17 datasets
(P = 0.54). However, there was between-study heterogene-
ity in the additive genetic model (P = 0.02) and recessive
genetic model (P = 0.03) for 16 datasets. In the subgroup
analyses by the type of cancers and ethnicity, as shown in
Figures 1 and 2, the heterogeneity test did not show any
significant difference in dominant genetic models: three
lung cancer studies (P = 0.10), six breast cancer studies (P
= 0.27), three bladder cancer studies (P = 0.86), two basal
cell carcinoma studies (P = 0.42), other cancers (ovarian,
prostate, and colorectal cancer) (P = 0.74), fourteen Cau-
casian population studies (P = 0.64), and two Chinese
population studies (P = 0.14).
Quantitative data synthesis
For the NSB1 E185Q polymorphism, the data available
for our meta-analysis were obtained from 17 datasets con-
sisted of 9,734 cases and 10,325 controls. Associations of
the NBS1 E185Q allele and genotypes with cancer risk
were estimated using dominant (GC+CC vs GG), additive
(CC vs GG), and recessive (CC vs GC +GG) genetic models
in either fixed or random effect models according the het-
erogeneity Q test in Table 2. There were 16 datasets in
these comparisons, except for Ryk's study that only
showed data in dominant genetic models. Compared
with the wild-type 8360 GG genotype, the carriers of var-
iant genotypes (i.e., GC/CC) had a 1.06-fold elevated risk
of cancer (95% CI = 1.00–1.12, P = 0.05) as estimated in
a fixed effect model for dominant genetic effects. We fur-
ther performed a sensitivity analysis, and found that when
Hebbring's study was excluded owing to the conflict of
Hardy-Weinberg equilibrium, the combined ORs of can-
cer risk was still 1.06 (95% CI = 1.00–1.12), and the P
value of the between-study heterogeneity test was
decreased significantly (from P = 0.54 to P = 0.48). How-
ever, the association between the NSB1 E185Q polymor-
phism and cancer risk was not significant in the additive
genetic model (CC vs GG) (OR = 0.98, 95% CI = 0.85–
1.13, P = 0.78) nor in the recessive genetic model (CC vs
GC + GG) (OR = 0.94, 95% CI = 0.82–1.07, P = 0.36).
The effect of 8360G>C (E185Q) polymorphism was fur-
ther evaluated in stratification analysis. By the types of
cancer, in those three lung cancer studies consisted of 605
cases and 639 controls, the variant genotypes (387 cases
and 395 controls) had a non-significantly increased risk of
lung cancer (OR = 1.08, 95% CI = 0.85–1.37, P = 0.54) as
estimated in a fixed effect model (Figure 1). In the six
breast cancer studies of 4,595 cases and 3,603 controls,
the variant genotypes (2,490 cases and 1,902 controls)
had a non-significantly increased risk (OR = 1.06, 95% CI
= 0.97–1.16, P = 0.18) (Figure 1). Similarly, in the three
bladder cancer studies of 1,446 cases and 1,452 controls
(OR = 1.13, 95% CI = 0.98–1.31, P = 0.10) and three basal
cell carcinoma studies of 770 cases and 1,107 controls
(OR = 1.11, 95% CI = 0.92–1.35, P = 0.27) (Figure 1).
In the stratification analyses for ethnicity, we found that
the increased risk of cancer associated with 8360G>C var-
iant genotypes was more pronounced in the Caucasians
(OR = 1.07, 95% CI = 1.01–1.14, P = 0.03), but not in
Chinese (OR = 0.84, 95% CI = 0.61–1.16, P = 0.30) nor in
Table 2: Summary of ORs for various comparisons
E185Q
comparison*
Population 
(number of data sets)§
Fixed-effects 
OR(95%CI)
Random-effects 
OR(95%CI)
Heterogeneity 
(P value Q test)
P value
(fixed)
P value
(random)
(GC+CC) vs GG 17 1.06(1.00–1.12) 1.06(1.00–1.12) 0.54 0.05 0.05
CC vs GG 16 0.99(0.90–1.09) 0.98(0.85–1.13) 0.02 0.83 0.78
CC vs (GC +GG) 16 0.95(0.87–1.04) 0.94(0.82–1.07) 0.03 0.28 0.36
C vs G 16 1.02(0.97–1.08) 1.02(0.98–1.07) 0.10 0.45 0.36
*Additive genetic model: CC vs GG, recessive genetic model: CC vs (GC +GG), dominant genetic model: (GC+CC) vs GG
§Ryk's study was not involved in 16 studies.BMC Cancer 2009, 9:124 http://www.biomedcentral.com/1471-2407/9/124
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African Americans (OR = 1.05, 95% CI = 0.86–1.30, P =
0.62) (Figure 2).
Bias diagnostics
To evaluate publication biases, the NSB1 E185Q geno-
types were plotted against the precision ones in a funnel
plot, which is approximately symmetrical. Egger's test sug-
gested that there was no publication bias in the current
meta-analysis (t = 0.15, df = 16, P = 0.88). Furthermore,
we found that the fail-safe number for the finding of NSB1
E185Q variant genotypes associated with 1.06 fold
increased risk of cancer was 60, which suggests that biases
Meta-analysis for NBS1 E185Q polymorphism variant genotypes (GC and CC) vs GG in different type of cancers (breast can- cer, lung cancer, bladder cancer, basal cell carcinoma, ovarian cancer, prostate cancer, and colorectal cancer) Figure 1
Meta-analysis for NBS1 E185Q polymorphism variant genotypes (GC and CC) vs GG in different type of can-
cers (breast cancer, lung cancer, bladder cancer, basal cell carcinoma, ovarian cancer, prostate cancer, and 
colorectal cancer).BMC Cancer 2009, 9:124 http://www.biomedcentral.com/1471-2407/9/124
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from publications and other factors may not have a signif-
icant influence on the results of current meta-analysis for
the association between NSB1 E185Q polymorphism and
cancer risk (Figure 3).
Discussion
In this meta-analysis consisted of 16 independent case-
control studies with 17 datasets, we found that the carriers
of  NBS1  E185Q variant genotypes had a 1.06-fold
increased risk of cancer in the dominant genetic model,
and the association was more pronounced in the Cauca-
sians. However, we did not find evidence for significant
associations in the subgroup analysis for the individual
type of cancers, such as lung cancer, breast cancer, basal
cell carcinoma, urogenital cancers (i.e., bladder cancer,
ovarian cancer, and prostate cancer), or colorectal cancer.
The  NBS1  8360G>C (rs1805794) polymorphism is a
non-synonymous SNP with an amino acid change
(Glu185>Gln or E185Q). Either one or two missense
changes in the dominant genetic model may affect the
function of NBS1 and interfere protein-protein interac-
tion [50]. The E185Q amino acid substitution was pre-
dicted to be tolerated via the SIFT prediction tool http://
blocks.fhcrc.org/sift/SIFT.html. The E185Q SNP is located
in a breast cancer carboxy-terminal (BRCT) domain (108–
196 amino acids) of NBS1 [3], and such a domain facili-
tates NBS1 to interact with BRCA1 (one of two familial
breast cancers mutated genes) forming BRCA1-associated
Meta-analysis for NBS1 E185Q polymorphism variant genotypes (GC and CC) vs GG in different ethnicities (Caucasians, Chi- nese and African Americans) Figure 2
Meta-analysis for NBS1 E185Q polymorphism variant genotypes (GC and CC) vs GG in different ethnicities 
(Caucasians, Chinese and African Americans).BMC Cancer 2009, 9:124 http://www.biomedcentral.com/1471-2407/9/124
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genome surveillance complex (BASC), which is responsi-
ble for the recognition and repair of aberrant DNA [51].
In the LD analysis, we found that the E185Q SNP was in
a completed LD (D' = 1.00, r2 = 1.00) with the loci
626G>A in the promoter of NBS1 (-1418 nt to initiation
transcription code ATG), 3816G>A (Leu34Leu,
rs1063045) and 40419A>G (Pro672Pro, rs1061302) [21].
In further bioinformatics analysis searching for the tran-
scription factor binding sites with the TFSEARCH program
http://mbs.cbrc.jp/research/db/TFSEARCH.html, we
found that the 626G allele, but not the 626A allele, creates
a new binding site of SRY that is a functional target of the
tumor suppression gene WT1  [52], and that the 626G
allele in LD with Glu185 may function in prohibiting car-
cinogenesis. Furthermore, in a region from 35309 bp
upstream to 29477 bp downstream of E185Q on chromo-
some 8, we found that there were thirty-three polymor-
phisms being in completely LD (all with an r2 = 1.00) with
E185Q (data not shown). Because the exact molecular
mechanism involving the NBS1 E185Q variant in the eti-
ology of cancer is still unclear, further investigations are
needed to identify its LD with other unknown functional
variants of cancer susceptibility candidate genes.
DNA DSBs in human cells is one of the major factors for
carcinogenesis. Affected individuals when exposed to dif-
ferent carcinogens will have different outcomes. For
example, the common NBS1 185Gln allele has been asso-
ciated with an increased risk for lung cancer in a Chinese
population exposed to smoky coal emissions [18]. Stable
covalent BaP DNA adducts can cause single-strand breaks,
resulting in DSBs during replication [53]. The established
risk factors for bladder cancer include cigarette smoking,
exposure to industrially related aromatic amines and
drugs [54,55]. Some common, low-penetrance suscepti-
bility genes in human populations may interact with radi-
ation exposure to increase risk of breast cancer [56],
because DNA DSBs are frequently induced by ionizing
radiation, which may result in altered apoptosis or tumor-
igenesis [1]. For ovarian cancer, however, ovulation may
play a role in ovarian cancer development [13]. Smoking
and drinking habit are frequently associated with colorec-
tal cancer risk [57]. BCCs are caused by interplay between
Funnel plot of the Egger's test of NBS1E185Q polymorphism for publication bias Figure 3
Funnel plot of the Egger's test of NBS1E185Q polymorphism for publication bias.BMC Cancer 2009, 9:124 http://www.biomedcentral.com/1471-2407/9/124
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genetic and environment factors, too [17]. The NBS1
E185Q variant genotypes (8360GC/CC) were found to be
associated with a p53 mutation in lung cancer, suggesting
a role in lung carcinogenesis [32]. Other report suggested
that the XRCC3  interacted with NBS1  involved in the
homologous recombination [58]. Therefore, it is likely
that the NBS1 E185Q polymorphism may modify cancer
susceptibility via gene-environment and gene-gene inter-
actions. However, not all studies offer the information
about environmental exposure.
Sensitivity analysis showed that for breast cancer no asso-
ciation (combined OR = 1.05, 95% CI = 0.99–1.11) was
present after exclusion of the study of Lu. In Lu's study the
subjects were ≤ 55 old women [21]. About 40% of NBS
patients develop cancer before the age of 21 [59]. It has
been suggested that there are different etiologic pathways
for early-onset and late-onset types of breast cancer
[60,61]. Therefore, large studies of NBS1 E185Q stratified
by age are needed to investigate the inter-individual sus-
ceptibility to cancer.
There appeared to be ethnicity-specific genetic effects,
because we found that the association between 8360G>C
variant genotypes and increased risk of cancer was signifi-
cant only in Caucasians but not in Chinese or African-
Americans, suggesting genetic diversity among different
ethnicities. The frequencies of 8360 C allele in the con-
trols of selected studies were not as similar as that from
the database of the International HapMap Project. We
would take that into account when applying to the find-
ings from the meta-analysis.
Potential publication bias may exist in this meta-analysis,
because the studies with negative results are more likely
not to be published, though there was no testable publi-
cation bias in our meta-analysis by the funnel plot.
Because there were only four out of 17 datasets were pop-
ulation-based case-control studies, others being hospital-
based case-control studies, the study subjects may not be
representative of the general population and could lead to
selection bias.
Conclusion
In conclusion, our meta-analysis suggests that based on
the published data, the NBS1 E185Q variant genotypes
(8360 GC/CC) might be associated with an increased risk
of cancer, especially in Caucasians. Due to the limitations
of such meta-analysis, larger association studies or multi-
centric case-control studies and the studies assessing gene-
environment interactions are warranted to confirm these
findings.
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